NY-ESO-1 TCR-engineered T cells + NY-ESO-1 peptide-pulsed dendritic cell vaccine + aldesleukin

This investigational combination immunotherapy regimen, developed at UCLA's Jonsson Comprehensive Cancer Center, represents a form of transgenic adoptive cell therapy (ACT). The regimen consists of autologous peripheral blood mononuclear cells (PBMCs) genetically engineered via a retroviral vector to express a T-cell receptor (TCR) specific for the NY-ESO-1 cancer-testis antigen. Following a nonmyeloablative conditioning regimen of fludarabine and cyclophosphamide, patients receive an infusion of these engineered T cells along with an autologous dendritic cell vaccine pulsed with the NY-ESO-1 (157-165) peptide. The dendritic cell vaccination is intended to stimulate the activation and expansion of the adoptively transferred T cells in vivo. Low-dose interleukin-2 (aldesleukin) is subsequently administered to support the persistence and proliferation of the engineered cells. This approach is primarily studied for the treatment of NY-ESO-1-expressing advanced malignancies, including melanoma and synovial sarcoma.

Other names

NY-ESO-1 TCR T-cells and DC vaccineNY-ESO1 TCR T-cells and DC vaccineNY-ESO 1 TCR T-cells and DC vaccineNY-ESO-1 TCR-engineered T cells + DC vaccine + IL-2Adoptive Transfer of NY-ESO-1 TCR Engineered PBMC with DC Vaccine and IL-2